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Abstract
Background: To determine, in a meta-analysis, the diagnostic performance of quantitative diffusion-weighted (DW)
MR imaging in patients with breast lesions.
Methods: English and Chinese studies published prior to June 2009 to assess the diagnostic performance of
quantitative DWI in patients with breast lesions were reviewed and summarized with reference to the inclusion
and exclusion criteria. Methodological quality was assessed by using the quality assessment of diagnostic studies
(QUADAS) instrument. Publication bias analysis was performed by using Comprehensive Meta-analysis version 2.
Meta-Disc version 1.4 was used to describe primary results and explore homogeneity by Chi-square test and
inconsistency index; to explore threshold effect by receiver operator characteristic (ROC) space and Spearman
correlation coefficient; and to pool weighted sensitivity and specificity by fixed or random effect model. A
summary ROC (sROC) curve was constructed to calculate the area under the curve (AUC).
Results: Of 65 eligible studies, 13 with 615 malignant and 349 benign lesions were included in the original meta-
analysis, among which heterogeneity arising from factors other than threshold effect and publication bias was
explored. Methodological quality was moderate. The pooled weighted sensitivity and specificity with
corresponding 95% confidence interval (CI) in one homogenous subgroup of studies using maximum b = 1000
s/mm2 were 0.84 (0.80, 0.87) and 0.84 (0.79, 0.88) respectively. AUC of sROC was 0.9085. Sensitivity analysis
demonstrated that the pooled estimates were stable and reliable.
Conclusions: Quantitative DWI has a higher specificity to differentiate between benign and malignant breast
lesions compared to that of contrast-enhanced MRI. However, large scale randomized control trials (RCTs) are
necessary to assess its clinical value because of disunified diffusion gradient factor b and diagnosis threshold.
Background
Breast cancer is the most common cancer in women
worldwide [1]. Despite the improvement in the detection
of breast cancer with the widespread application of
mammography and ultrasound, differentiation between
benign and malignant breast lesions remains a difficult
diagnosis problem, especially in dense fibroglandular
breasts. Numerous studies have been performed to
assess the diagnostic performance of contrast-enhanced
magnetic resonance imaging (MRI) in breast lesions
[2-5]. Based on the enhancement pattern of lesions and
morphologic changes, breast MRI offers an overall sensi-
tivity of 90% and specificity of 72% in detecting breast
lesions according to a published Meta-analysis [6].
Therefore, the classification of a lesion detected on MRI
as benign or malignant remains a challenge [6,7].
One of the latest advancements in MRI technology is
the application of diffusion-weighted imaging (DWI) to
offer quantitative evaluation of apparent diffusion coeffi-
cient (ADC). Quantitative DWI is a powerful imaging
tool which provides unique information related to the
diffusion of water molecules in the tissue and allows
estimation of cellularity and tissue structure [8].
Restricted water movement in tumors with high cellu-
larity usually leads to higher signal intensity and smaller
ADC value [7,9]. ADC is measured by acquiring the MR
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signal at least twice, typically with and without diffusion
weighting by the following formula: ADC = [In (S0/Sb)]/
b, where Sb and S0 are the signal intensities on the DW
imaging with and without diffusion weighting, respec-
tively [10]. Theoretically, the diffusion sensitivity is easily
varied by changing the diffusion gradient factor known
as the “b value” which is proportional to the gradient
amplitude, the duration of the applied gradient and the
time interval between the paired gradients [8].
The potential role of quantitative DWI in characteriz-
ing breast lesions has been reported [11-18]. However,
the reported sensitivity and specificity of diagnosing
malignant breast tumors ranged from 62.5% to 92.8%
and 45.8% to 96.7%, respectively. Comparison of the
diagnostic performance of breast quantitative DWI
among the studies may have been compromised by
differences in the patient characteristics, MR imaging
techniques, and diagnostic criteria for malignancy in the
studies. In this study, we pool a number of DWI studies
of the breast to evaluate the diagnostic performance of
DWI in breast lesion characterization.
Methods
Literature Search
The MedLine and CNKI (China National Knowledge
Infrastructure) search were performed (Li WL and Bai
ZL; MAY 20, 2009) by using the terms “Diffusion-
Weighted Imaging [MeSH] or DWI” for the diagnostic
test and “Breast Neoplasms [MeSH] or breast cancer or
breast lesions or breast” for the clinical domain. Terms
regarding diagnostic performance were excluded in our
search criteria to minimize missing relevant studies. We
limited our search to publications in English and Chi-
nese languages, female subjects, search term presence in
the title or abstract of the article and publication date
no later than May 2009. The Cochrane library, Ovid,
Elsevier and Springer databases were also searched (Li
WL; June 10, 2009) for research articles with the same
criteria. Review articles, letters, comments, case reports
and unpublished articles were excluded. Extensive cross-
checking of the reference lists of all retrieved articles
was performed to supplement the list of articles.
Selection of Articles
Inclusion criteria were: varied pathology within the data-
set; total number of lesions ≥ 30, with the number of
both malignant and benign lesions each ≥ 10; histo-
pathologic analysis (performed at surgery and biopsy)
and follow-up by ultrasound, mammography, or MRI
used as the reference standards; Sufficient information
were presented to calculate the true-positive (TP), false-
positive (FP), true-negative (TN) and false-negative (FN)
values for per-lesion statistics; When same data or
subsets of data were presented in more than one article,
the article with the most details and/or most recently
published was chosen.
Articles were selected by two steps according to the
road map of diagnostic systematic reviews and guide-
lines [19]. First, articles were excluded after inclusion
and exclusion criteria were applied to the titles and
abstracts of the articles fulfilling the search criteria. We
then determined the final studies included in the meta-
analysis after applying the same inclusion and exclusion
criteria to the remaining content of the articles.
Studies were excluded if results of different MR ima-
ging series (such as contrast-enhanced imaging and
DWI) were presented in combination and could not be
differentiated for performance assessment of tests on
only DWI series.
Quality Assessment and Data Extraction
Two observers (Chen X and Zhang YL) independently
selected eligible articles and extracted relevant data
about study characteristics and examination results from
each article by using a standardized form. To resolve
disagreement between reviewers, a third reviewer (Guo
YM) assessed all involved items. The majority opinion
was used for analysis.
Methodological quality of included studies was
assessed independently by two observers using the qual-
ity assessment of diagnostic studies (QUADAS) instru-
ment, a quality assessment tool specifically developed
for systematic reviews of diagnostic accuracy studies
[20,21].
The author, study nation, year of publication, number
and age of subjects, and diagnostic test characteristics
including b values, mean ADC values of malignant and
benign lesions, and diagnostic threshold for malignant
lesions were extracted from each study.
Values for TP, FP, TN, FN, sensitivity (SEN), specifi-
city (SPE), accuracy (ACC), positive predictive value
(PPV), negative predictive value (NPV), positive likeli-
hood ratio (PLR) and negative likelihood ratio (NLR)
results in the detection of malignant lesions were
extracted. SEN, SPE, ACC, PPV, NPV, PLR and NLR
were calculated by the following formulas:
SEN TP TP FN
SPE TN FP TN
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All tabulated results for different readers (interobser-
ver), for multiple observations per reader (intraobserver)




We used the Q statistic of Chi-square value test and
inconsistency index (I-squared, I2) to estimate the het-
erogeneity of individual studies contributing to the
pooled estimate. The homogeneity was to evaluate if the
differences across the studies were greater than expected
by chance alone. P < 0.05 suggests presence of heteroge-
neity beyond what could be expected by chance alone.
I-squared (I2) describes the percentage of total variation
across studies due to heterogeneity rather than chance
and was also used as a measure to quantify the amount
of heterogeneity. I2 > 50% suggests heterogeneity [22].
Threshold effect
Different thresholds may be used in included studies to
define a positive test result due to lack of standardiza-
tion. Differential threshold effect may be the reason for
detectable difference in sensitivities and specificities of
test accuracy studies. Representation of accuracy esti-
mates from each study in a receiver operating character-
istic (ROC) space and computation of Spearman
correlation coefficient between the log (SEN) and log
(1-SPE) were assessed for threshold effect. A typical
pattern of “shoulder arm” plot in a ROC space and a
strong positive correlation would suggest threshold
effect [23,24].
Publication bias analysis
Studies with optimistic results are more likely to be
submitted and accepted for publication than studies
with unfavorable results. Since publication biases would
tend to exaggerate clinical effects resulting in potentially
erroneous clinical decision making, it is important to
assess the likely extent of the bias and its potential
impact on the conclusions [25]. Publication bias can be
visually examined after construction of a funnel plot and
quantitatively detected by fail-safe N (NFS). In the
absence of publication bias, the data points form a sym-
metric funnel-shaped distribution, whereas an asym-
metric distribution indicates the presence of publication
bias [26]. NFS refers to the exact number of hypotheti-
cal studies with null results that would be required to
nullify the statistical significance of combined effect
[27]. A relatively small NFS should be cause for con-
cern. However, if NFS is large, we can be confident the
combined effect, while possibly inflated by the exclusion
of some studies, is nevertheless not zero [28].
Statistical pooling
Statistical pooling is not always necessary in every
systematic review of test accuracy studies. The necessary
precondition for pooling estimates is that the studies
and results are reasonably homogeneous. The estimates
can be pooled by the fixed effect model (FEM) or by the
random effect model (REM) to incorporate variation
among studies, and the output can be presented graphi-
cally as forest plots. If heterogeneity due to threshold
effect is present, the accuracy data can be pooled by
fitting a summary ROC (sROC) curve and summarizing
that curve by means of the area under the curve (AUC).
A sROC curve summarizes and combines the true and
false positive rates from different diagnostic studies. The
overall performance of diagnostic studies can be visua-
lized and reflected by a sROC curve without being
affected by a change of threshold values [29]. The best
diagnostic modality would yield a point in the upper left
corner or coordinate (0, 1) of the sROC space, repre-
senting 100% sensitivity (no false negatives) and 100%
specificity (no false positives) at the individual subject
level. Similarly, AUC ranges from 1 for a perfect test
that always diagnoses correctly, to 0 for a test that never
does so in single studies or meta-analyses. If there is
heterogeneity due to sources other than threshold effect,
pooling should only be attempted within homogeneous
subsets [23].
Sensitivity analysis
The pooled estimates were reappraised when suspicious
studies were excluded, and the reappraised results were
compared with the original results to assess stability and
reliability of our meta-analysis.
The homogeneity test, threshold effect analysis, pooled
weighted sensitivity and specificity, sROC curve and
sensitivity analysis were performed by using Meta-Disc
version 1.4 [23]. Publication bias analysis was performed
by using Comprehensive Meta-analysis version 2 [30].
Results
With the computer search and manual cross-checking
of reference lists, 65 abstracts (26 English and 39 Chi-
nese) were retrieved. After reading the titles and
abstracts, we found 25 eligible articles (15 English and
10 Chinese). After reading the full texts, we excluded
12 of the 25 relevant articles for the following reasons:
The objective of studies was not to explore the diag-
nostic performance of 1.5 T MR DWI on breast
lesions [31-34] (n = 4); Benign breast lesions in the
study were all fibroadenomas [35] (n = 1); Researchers
did not report data that could be used to construct or
calculate TP, FP, TN and FN results [15,17,36]
(n = 3); Researchers presented results from a combina-
tion of different MR series that could not be differen-
tiated for assessment of single DWI [37] (n = 1); Data
or subsets of data were presented in other articles
[38,39] (n = 2). Thirteen articles (5 English and 8 Chi-
nese) fulfilled all inclusion and exclusion criteria and
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were selected for data extraction and data analysis
[11,13,14,16,18,40-47].
Nine hundred and sixty four breast lesions (615 malig-
nant, 349 benign) were included from 13 studies. The
mean ADC values of malignancy ranged from 0.87 to
1.36 × 10-3 mm2/s. The mean ADC values of benign
lesions ranged from 1.00 to 1.82 × 10-3 mm2/s. The cut-
off values differentiating malignant and benign lesions
ranged from 0.90 to 1.76 × 10-3 mm2/s while the sensi-
tivity and specificity ranged from 63% to 100% and 46%
to 97%, respectively. The abstracted data of these indivi-
dual studies are summarized in Tables 1 and 2. Two or
multiple subsets of data in one study were included
because: The two methods of echo planar imaging (EPI)
and half-Fourier acquired single-shot turbo spin echo
(HASTE) were used to perform breast DWI in Baltzer
et al. [40]; Marini et al. used 1.1 × 10-3 mm2/s (mean
diffusivity of benign lesions - 1 SD) and 1.31 × 10-3
mm2/s (mean diffusivity of malignant lesions -2 SD) as
cutoff between benign and malignant breast lesions [18];
ADC values were measured by two radiologists indepen-
dently in Rubesova et al. [14]; Multiple b values were
used in some studies [41,42,44,45].
Results of distribution of study design characteristics
in 13 studies according to QUADAS items are shown in
Table 3. Most studies have a suboptimal design in
regard to the reporting of selection criteria (67.2% for
“yes” responses to question 2), the description of the
execution of the reference standard (76.9% for “no”
responses to question 9), the interpretation of the refer-
ence standard results without knowledge of the index
test results and the interpretation of the index test
results without knowledge of the reference standard
(84.6% and 100% for “unclear” responses to question 10
and 11 respectively), reporting of uninterpretable and/or
intermediate test results (69.2% for “no” responses to
question 13) and explanation of withdrawals from the
study (76.9% for “no” responses to question 14).
The forest plots of sensitivities and specificities from
23 subsets of data from all 13 studies are shown in
Figure 1. A homogeneity test of sensitivity and specifi-
city shows Q = 58.20 (P < 0.0001), I2 = 62.2% and
Q = 61.44 (P < 0.0001), I2 = 64.2%, respectively. There-
fore, notable heterogeneities are detected. The next step
is the representation of sensitivity against 1-specificity
from each study in a ROC space to explore the thresh-
old effect. The pattern of the points in this plot is not a
“shoulder-arm” shape (Figure 2). A Spearman rank
correlation is performed as a further test for threshold
effect. The Spearman correlation coefficient was equal
to 0.097 (P = 0.66) and indicates that there should be
other factors than threshold effect resulting in variations
in accuracy estimates among individual studies.
The funnel plot in Figure 3 shows that the studies are
distributed symmetrically about the combined effect size
and yield a z-value of 4.46191 with corresponding
P-value of 0.00001. The NFS is 92. This means that we
would need to locate and include 92 “null” studies in
order for the P to exceed 0.05. There is no significant
publication bias, and actual combined effect size is equal
to the theoretical combined effect size.
Having found notable heterogeneity beyond threshold
effect and publication bias, we then focus on the
subgroup of studies using maximum b = 1000 s/mm2.
A homogeneity test of sensitivity and specificity shows
Q = 16.39 (P = 0.1271), I2 = 32.9% and Q = 15.81 (P =
0.1483), I2 = 30.4% respectively. The pooled weighted
sensitivity and specificity with corresponding 95% CIs
Table 1 The characteristics of included studies
Author Publication
Year










Baltzer(40) 2009 Germany 54 (N) 65 74 35 39
Marini(18) 2007 Italy 53 (24-79) 60 63 21 42
Rubesova
(14)
2006 Belgium 52 (25-74) 78 87 22 65
Woodhams
(13)
2005 Japan 53 (14-88) 190 191 24 167
Guo(11) 2002 China 58 (25-75) 52 55 24 31
Huang(41) 2008 China 50 (31-77) N 56 24 32
Jin(42) 2008 China N (N) 56 60 20 40
Tang(43) 2008 China 51 (33-76) 48 70 25 45
Gu(44) 2008 China 51 (33-83) 83 95 52 43
Lou(45) 2007 China 42 (18-71) 50 58 26 32
Luo(16) 2007 China 43 (24-65) 52 60 33 27
Li(46) 2005 China 45 (24-68) 35 41 13 28
Zhao(47) 2005 China 43 (21-72) 46 54 30 24
Note: N = not mentioned
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are 0.84 (0.80, 0.87) and 0.84 (0.79, 0.88) (Figure 4)
respectively, and expressed as AUC of sROC curve is
0.9085 (Figure 5).
Heterogeneity, the pooled weighted sensitivity and
specificity, and AUC are analyzed again when [46] and
[47] were excluded respectively due to the seemingly
differential sensitivity and specificity from others
(Table 4). The pooled sensitivity and specificity is simi-
lar, and the corresponding 95% CIs are predominantly
overlapped with each other. The homogeneity is not
reversed. The results of sensitivity analysis demonstrate
that the pooled estimates are stable and reliable.
Discussion
In this meta-analysis, we calculate an overall sensitivity
of 0.84 (95% CI: 0.82, 0.87) and specificity of 0.79 (95%
CI: 0.75, 0.82) from 13 studies fulfilling all inclusion and
exclusion criteria. However, there is notable heterogene-
ity among individual studies. Therefore, it is critical to
investigate the source of heterogeneity to determine the
potential impact factors and to evaluate the appropriate-
ness of statistical pooling of accuracy estimates from
various studies.
Meta-Disc is performed to assess threshold effect from
representation of accuracy estimates from each study in
a ROC space, and Spearman correlation coefficient is
computed between the log (SEN) and log (1-SPE). Lack
of “shoulder-arm” shape of the points in the ROC space
and mild Spearman correlation coefficient (0.097) indi-
cate that there should be factors other than differences
in cutoff points for malignancy causing variations in
accuracy estimates across individual studies. Addition-
ally, publication bias is an usual source of heterogeneity
in meta-analysis. Publication biases might exaggerate
clinical effects resulting in potentially erroneous clinical
decision making. In systematic reviews or meta-analysis,
a thorough literature search is crucial to identify all rele-
vant studies. In this meta-analysis, the search of several
electronic databases is supplemented by checking refer-
ences of relevant studies in order to reduce publication
bias [25]. Although only English and Chinese articles are
searched, the funnel plot and NFS analysis indicate that
there is no significant publication bias in our meta-
analysis.
The parameters used in DWI sequences may affect the
results of ADC calculation, and the diffusion gradient
factor b is one of important parameters [8]. The varia-
bility in b values across studies makes the ranges and
thresholds of ADC values difficult to interpret. Because
b values used in the included studies varied, we needed
Table 2 The ADC measurement of included studies (×10-3mm2/s) ( x ± SD).
Author B value (s/mm2) Mean ADC of malignant Mean ADC of benign Mean ADC of normal Threshold
Baltzer 0, 750, 1000 1.05 ± 0.33 1.63 ± 0.42 N 1.23
0, 800 1.09 ± 0.38 1.67 ± 0.40 N 1.24
Marini 0, 1000 0.95 ± 0.18 1.48 ± 0.37 N 1.10
1.31
Rubesova 0, 200, 400, 600, 800, 1000 0.95 ± 0.02 1.51 ± 0.07 N 1.15
0.99 ± 0.03 1.47 ± 0.08 N 1.10
Woodhams 0, 750 1.22 ± 0.31 1.67 ± 0.54 2.09 ± 0.27 1.60
Guo 0, 1000 0.97 ± 0.20 1.57 ± 0.23 N 1.30
Huang 0, 500 1.02 ± 0.18 1.61 ± 0.32 1.67 ± 0.21 1.32
0, 1000 0.99 ± 0.16 1.59 ± 0.33 1.65 ± 0.21 1.25
Jin 0, 600 1.33 ± 0.36 1.82 ± 0.31 2.05 ± 0.33 1.44
0, 1000 1.08 ± 0.32 1.61 ± 0.33 1.85 ± 0.33 1.18
Tang 0, 800 1.15 ± 0.19 1.47 ± 0.25 N N
0, 1000 1.08 ± 0.19 1.42 ± 0.26 N 1.38
Gu 0, 500 1.36 ± 0.38 1.64 ± 0.34 1.77 ± 0.39 1.5
0, 1000 1.18 ± 0.31 1.39 ± 0.32 1.56 ± 0.33 1.3
0, 2000 0.82 ± 0.20 1.00 ± 0.23 0.90 ± 0.27 0.90
Lou 0, 400 1.28 ± 0.48 1.71 ± 0.42 2.06 ± 0.48 1.76
0, 600 1.18 ± 0.41 1.59 ± 0.41 1.92 ± 0.53 1.64
0, 800 1.11 ± 0.41 1.70 ± 0.34 1.82 ± 0.48 1.52
0, 1000 1.05 ± 0.38 1.55 ± 0.35 1.75 ± 0.52 1.43
Luo 0, 800 0.87 ± 0.23 1.59 ± 0.26 1.98 ± 0.31 1.22
Li 0, 1000 1.21 ± 0.26 1.49 ± 0.43 N 1.42
Zhao 0, 1000 0.91 ± 0.25 1.58 ± 0.22 1.78 ± 0.51 1.01
Note: N = not mentioned; ADC = apparent diffusion coefficient; SD = standard deviation.
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to explore whether b values were the source of hetero-
geneity. Meta-analysis is performed again in the sub-
group of studies using maximum b = 1000 s/mm2
because more studies used b at 1000 s/mm2 than any
other value from Table 2. The results show that there is
no significant heterogeneity, and the pooled sensitivity
and specificity with 95% CIs are 0.84 (0.80, 0.87) and
0.84 (0.79, 0.88) respectively. The area under the curve
Figure 1 Forest plots of sensitivity and specificity, with corresponding 95% CIs from all eligible studies.










1 Patient spectrum Y Y Y Y Y Y Y Y Y Y Y Y Y 100 0 0
2 Reporting of selection
critetia
Y Y Y Y N N Y Y N N Y Y Y 69.2 30.8 0
3 Reference standard Y Y Y Y Y Y Y Y Y Y Y Y Y 100 0 0
4 Absence of disease
progression bias
Y Y Y Y Y Y Y Y Y Y Y Y Y 100 0 0
5 Absence of partial
vertification bias
Y Y Y Y Y Y Y Y Y Y Y Y Y 100 0 0
6 Absence of differential
vertification bias
N N Y Y N Y Y Y Y Y Y N Y 69.2 30.8 0
7 Absence of incorporation
bias
Y Y Y Y Y Y Y Y Y Y Y Y Y 100 0 0
8 Description of index text
execution
Y Y Y Y Y Y Y Y Y Y Y Y Y 100 0 0
9 Description of reference
standard execution
Y N N N Y N N N Y N N N N 23.1 76.9 0
10 Absence of test review
bias
Y U U U U Y U U U U U U U 15.4 0 84.6
11 Absence of diagostic
review bias
U U U U U U U U U U U U U 0 0 100
12 Absence of clinical review
bias




N N Y N Y N N Y N N Y N N 30.8 69.2 0
14 Withdrawal Y U Y U Y U U U U U U U U 23.1 76.9 0
Note: Y = yes; N = no; U = unclear; QUADAS = quality assessment of diagnostic studies.
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of sROC is 0.9085. Compared with the original results
from all 13 eligible studies, the specificity is improved.
However, we could not determine effect of other b
values to pooled accuracy estimates because of the
relatively small number of included studies. Further-
more, sensitivity analysis is performed in the subgroup
of b = 1000 s/mm2. When the studies with the maxi-
mum variance of sensitivity and specificity are excluded
in sequence, the characteristics of heterogeneity are not
changed and the variances of the pooled accuracy esti-
mates are not significant. The sensitivity analysis shows
that this meta-analysis in the subgroup is stable.
A previously published meta-analysis for contrast-
enhanced MRI including 44 studies reported the overall
sensitivity of 0.90 (95% CI: 0.88, 0.92) and specificity of
0.72 (95% CI: 0.67, 0.77) in patients with breast lesions
[6]. In comparison, our meta-analysis indicates that
DWI has higher specificity but lower sensitivity. How-
ever, several differences and limitations in our meta-ana-
lysis should be noted. The significance of Peter et al. [6]
lies in the diagnostic performance of MR imaging of
small lesions detected at mammographic screening.
Because a large proportion of these lesions are nonpalp-
able, they only include studies that enrolled at least one
patient with nonpalpable lesion [6]. In our meta-analy-
sis, we do not filter the studies using such criteria. In
the included studies, Marini et al. selected lesions with
diameter >1 cm [18]. Rubesova et al. selected lesions
with diameter > 0.7 cm [14], and Tang et al. selected
lesions with diameter ≤ 2 cm [43]. Lesion diameter ran-
ged from 0.3 to 9 cm for other included studies. It is
not certain that smaller lesions could be more easily
missed in DW images since no included studies
reported the number of nonpalpable lesions. Such varia-
tion might affect the overall estimates of the sensitivity
and specificity. Because MR is one of the important
methods for breast cancer diagnosing, DWI, having the
advantages of a short examination time and no need to
inject a contrast medium could be used in screening
crowd to early detect nonpalpable lesions and to gener-
ate significant benefits to early tumor diagnosis and
human health care needs in the future.
One limitation of our study is the suboptimal quality
of included studies. Meta-analysis combines or inte-
grates the results of several independent studies. The
quality and reliability of a meta-analysis depends on the
quality of included studies. We use the QUADAS tool
for assessing methodological quality of individual stu-
dies. This tool was specifically developed for quality
assessment of diagnostic accuracy studies included in
systematic reviews and has been used to help identify
severe methodological shortcomings [21]. Most included
studies in this meta-analysis had a suboptimal design in
regard to the reporting of selection criteria, the descrip-
tion of the execution of the reference standard, the
interpretation of the reference standard results without
knowledge of the index test results, the interpretation of
the index test results without knowledge of the refer-
ence standard, reporting of uninterpretable and/or inter-
mediate test results, or explanation of withdrawals from
the study (Table 3).
In test accuracy studies, interpretation of the results of
the index test may be influenced by knowledge of the
results of the reference standard, and vice versa. This is
known as review bias and may lead to inflated measures
of diagnostic accuracy. As the index test, DWI was
always performed first, and interpretation of the results
of the DWI was usually done without knowledge of the
results of the reference standard. However, if test result
was interpreted at a later date, after both DWI and
Figure 3 Funnel plot of eligible studies. Note: White flakes
represent published articles, and red flake represents possibly
missed article. White and red rhombuses represent actual and
theoretical combined effect size respectively.
Figure 2 Sensitivity and 1-specficity plotted in receiver
operating characteristic space for individual studies.
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reference standard had been completed, then it was still
important for a study to provide a description of
whether the interpretation of each test was performed
blind to the results of the other tests. Uninterpretable
results produced in test accuracy studies are often not
reported. Instead, they are simply removed from the
analysis. This problem may lead to the biased assess-
ment of the test characteristics. Whether bias will arise
Figure 5 SROC curve for studies using maximum b = 1000 s/mm2.
Figure 4 Forest plots of sensitivity and specificity, with corresponding 95% CIs from studies using maximum b = 1000 s/mm2.
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depends on the possible correlation between uninterpre-
table test results and the true disease status. If uninter-
pretable results occur randomly and are not related to
the true disease status of the individual, these should not
have any effect on test performance. However, whatever
the cause of uninterpretable results, it is important that
they are reported so that the impact of these results on
test performance can be determined. Patients’ withdrawal
from the study can occur prior to the results of either or
both of the index test and reference standard in diagnos-
tic studies being available. If patients lost to follow-up
differ systematically from those who remain in studies,
then estimates of test performance may be biased. There-
fore, it is important to report patients lost to follow-up.
In brief, most studies in evaluating the diagnostic values
of DWI for breast lesions had some clinical operational
challenges. Therefore a systematic data reporting method
such as the standards for reporting diagnostic accuracy
(STARD) should be advocated to improve the quality of
reporting test accuracy studies [48].
All of individuals showed that the mean ADC value of
malignant lesions was lower than that of benign lesions.
However, the reported mean ADC values of malignant
and benign tumors ranged from 0.87 to 1.36 and 1.00 to
1.82 × 10-3 mm2/s, respectively, resulting in recom-
mended threshold values of ADC ranging from 0.90 to
1.76 × 10-3 mm2/s. Even in the subgroup of studies
using maximum b = 1000 s/mm2, the minimum and
maximum threshold values were 1.10 × 10-3 mm2/s
[14,18] and 1.38 × 10-3 mm2/s [43], respectively. The
substantial variance of threshold values might be influ-
enced by different b values, selection method, bias of
patient selection, pathological characteristic of lesions
and measurement of ADC values. This meta-analysis
does not seem to predict or determine the unified
threshold value to differentiate malignant and benign
breast lesions because selection of the threshold value
should be determined according to the purpose of
examination. For example, a relatively higher threshold
value may be recommended to minimize missing malig-
nancy in breast cancer screening. If DWI is appended to
the contrast-enhanced MRI, a relatively lower threshold
value may be recommended to reduce false positive
results.
Conclusion
ADC measurement of DWI is useful for differentiation
between malignant and benign breast lesions with
pooled sensitivity of 0.84 and specificity of 0.84 in one
homogenous subgroup of studies using maximum
b = 1000 s/mm2, and the area under curve of sROC
was 0.9085. DWI has a higher specificity but lower
sensitivity compared to that of contrast-enhanced
MRI. However, with all of methodological issues con-
sidered, results must be interpreted with caution.
Large scale randomized control trials (RCTs) are
necessary to assess and confirm its clinical value. A
threshold value for malignant/benign lesions classifica-
tion could not be made based on this study because it
is influenced by different b values, bias of patient
selection, lesions ’ pathological characteristics and
ADC measurement. Selection of the threshold value
should be determined according to the purpose of
examination.
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